AETERNA ZENTARIS INC. (ET80.MU)
| Previous close | 7.80 |
| Open | 7.80 |
| Bid | 7.66 x N/A |
| Ask | 7.92 x N/A |
| Day's range | 7.80 - 7.80 |
| 52-week range | 5.52 - 11.30 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAeterna Zentaris Announces Details Regarding Transaction with Ceapro
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously announced merger of equals transaction (the “Transaction”) with Ceapro Inc. (“Ceapro”). On May 3, 2024, the Company completed a share consolidation (or reverse stock split) (the “Consolidation”) of its common shares (the “Common Shares”) on the basis of one post-Consolidation Common Share for every fou
- GlobeNewswire
Aeterna Zentaris Reports First Quarter 2024 Financial Results
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third quarter of 2024All-stock merger of equals transaction with Ceapro Inc. expected to close in the second quarter of 2024 TORONTO, ONTARIO, May 14, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and c
